Premium
Differential effects of antidepressant subgroups on risk of acute myocardial infarction: A nested case–control study
Author(s) -
AlqdwahFattouh Rasha,
RodríguezMartín Sara,
Abajo Francisco J.,
GonzálezBermejo Diana,
Gil Miguel,
GarcíaLledó Alberto,
Bolúmar Francisco
Publication year - 2020
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14299
Subject(s) - nested case control study , medicine , trazodone , odds ratio , clomipramine , serotonin reuptake inhibitor , myocardial infarction , case control study , confidence interval , antidepressant , hippocampus
Aims The primary objective of this study was to investigate the association between antidepressants use and the risk of acute myocardial infarction (AMI). Methods We conducted a nested case–control study using a primary care database over the period 2002–2015. From a cohort of patients aged 40–99 years, we identified incident AMI cases and randomly selected 5 controls per case, matched to cases for exact age, sex and index date. Exposure to antidepressants were categorised as current, recent, past and nonusers. Adjusted odds ratio (AOR) and 95% confidence interval (CI) were computed using conditional logistic regression to assess the association between the current use of different antidepressants subgroups and AMI as compared to nonuse. Dose and duration effects were explored. Results Totals of 24 155 incident AMI cases and 120 775 controls were included. The current use of antidepressants as a group was associated with a reduced risk (AOR = 0.86; 95% CI: 0.81–0.91), but mainly driven by selective serotonin reuptake inhibitors (AOR = 0.86; 95% CI:0.81–0.93). A reduced risk was also observed with trazodone (AOR = 0.76;95% CI: 0.64–0.91), and clomipramine (AOR = 0.62; 95% CI: 0.40–0.96), whereas no significant effect was observed with other antidepressants. A duration‐dependent effect was suggested for selective serotonin reuptake inhibitors, trazodone and clomipramine, while there was no clear dose‐dependency. Conclusion This study suggests that current use of antidepressants interfering selectively with the reuptake of serotonin, and those antagonizing the 5‐HT 2A receptor, are associated with a decrease in AMI risk and should be the antidepressants of choice in patients at cardiovascular risk.